Monday, November 21, 2011
Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women with Hormone Receptor-Positive Metastatic Breast Cancer and Bone Metastases
(
EXEL
,
IST
,
News
,
FDA
/ Mon, 07:49am)